Crescent Biopharma, Inc. (CBIO) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.09: Risk below floor (2.4 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002,... Read more
Sell if holding. Engine safety override at $17.09: Risk below floor (2.4 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Crescent Biopharma, Inc.
Latest news
- NEWS Crescent Biopharma Files Prospectus For Offering $500M Mixed Shelf — benzinga Jul 1, 2026 positive
Generated 2026-07-05T09:50:25Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 7.4% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.09: Risk below floor (2.4 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.00. Score 4.8/10, moderate confidence.
Take-profit target: $26.97 (+57.8% upside). Prior stop was $16.00. Stop-loss: $16.00.
Risk below floor (2.4 < 3.0).
Crescent Biopharma, Inc. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 5.4/10. Verdict: Sell.
15 analysts cover CBIO with a consensus score of 4.3/5. Average price target: $31.
What does Crescent Biopharma, Inc. do?Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United...
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.